Meta-analysis of 58 phase 3 RCTs (22 590 patients): treatment-related peripheral edema affected 2.80% on immune checkpoint inhibitor monotherapy, 4.96% with chemotherapy and 8.73% with targeted therapy; monotherapy vs chemotherapy OR 0.45 (95% CI 0.27–0.73).
Meta-analysisn = 22,590
Markus et al. Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis